ARA-290 dose guide

ARA-290 dosage

Eleven amino acids copied from the water-facing side of one helix in erythropoietin, the hormone that drives red-cell production — residues that sit side by side on that face, strung into a new chain rather than a stretch cut out of the hormone. That face reaches a repair receptor and misses the red-cell receptor, so it keeps EPO's tissue-protective half of the signal without the thickened blood. It is the one compound in this library whose human trials are specifically about nerve symptoms. Commonly reported: burning and tingling settling over the first one to two weeks, often with nothing to feel for a while first; one user who ran it for a pinched nerve noticed no change. Four small randomized trials exist and no approval.

Dose range

1–4 mg (research range). Studied in research — not a recommendation.

How often

Daily

A typical run

4 weeks, often repeated. The published daily courses ran 28 days (three trials) and 12 weeks (the eye study). Community runs commonly last about four weeks and are repeated later. In the trial that followed people longest, the symptom improvement was still measurable 12 weeks after the last dose, and nine months after; nothing beyond 12 weeks of daily dosing has been studied.

How it’s taken

Vial: SubQ injection

Evidence

Moderate: Animal studies + some human data

Half-life

~20 minutes (measured in healthy volunteers after a SubQ dose; about 2 minutes after IV, and its developers argue a brief exposure is enough because the receptor acts as a switch)

ARA-290 on your syringe

With a 10 mg vial and 2 mL of water (5 mg in every mL), on a 1 mL (100-unit) U-100 insulin syringe: the low end, 1 mg, is 20 units; and the high end, 4 mg, is 80 units. 10 doses in the vial at the low end. All U-100: 100 units to the mL. A U-40 syringe reads differently.

ARA-290 in the peptide libraryThe Dose Guide: every peptide

More healing peptides

• BPC-157 200–500 mcg
• TB-500 1–2.5 mg
• GHK-Cu 1–2 mg
• KPV 100–300 mcg
• AOD-9604 250–300 mcg
• Thymosin Alpha-1 1–1.6 mg
• Thymosin Beta-4 2–2.5 mg
• LL-37 100–300 mcg
• Larazotide 0.5–1 mg
• VIP 50 mcg
• Cartalax No reference dose
• Ac-SDKP 250–750 mcg

A community reference, not medical advice. Each range is what has been studied or is commonly run, never a dose for you.